Development of a photosensitizing drug using replication-deficient virus particles and talaporfin sodium for photodynamic therapy of prostate cancer

カテゴリ: 研究会(論文単位)

論文No: OQD17015

グループ名: 【C】電子・情報・システム部門 光・量子デバイス研究会

発行日: 2017/03/06

タイトル(英語): Development of a photosensitizing drug using replication-deficient virus particles and talaporfin sodium for photodynamic therapy of prostate cancer

著者名: Saito Sachiko(Osaka University),Inai Mizuho(Osaka University),Honda Norihiro(Osaka University),Hazama Hisanao(Osaka University),Kaneda Yasufumi(Osaka University),Awazu Kunio(Osaka University)

著者名(英語): Sachiko Saito(Osaka University),Mizuho Inai(Osaka University),Norihiro Honda(Osaka University),Hisanao Hazama(Osaka University),Yasufumi Kaneda(Osaka University),Kunio Awazu(Osaka University)

キーワード: photodynamic therapy|hemagglutinating virus of Japan envelope|talaporfin sodium|prostate cancer|photodynamic therapy|hemagglutinating virus of Japan envelope|talaporfin sodium|prostate cancer

要約(日本語): Replication-deficient virus particles, hemagglutinating virus of Japan envelope (HVJ-E), has cytotoxicity to cancer cells, and clinical research on prostate cancer is conducted. To enhance the therapeutic effect of HVJ-E, talaporfin sodium (Laserphyrin?) used for photodynamic therapy (PDT) was encapsulated into HVJ-E to produce a novel photosensitizing drug, Laserphyrin?-HVJ-E, and its therapeutic effect for prostate cancer cells (PC-3) was evaluated. As the results, direct cytotoxicities of HVJ-E and Laserphyrin?-HVJ-E for PC-3 after an administration time of 48 h were almost the same. After PDT with administration of Laserphyrin?-HVJ-E and Laserphyrin? for 10 min, cell survival rates of PC-3 were about 21% and 19%, respectively. Although further study is needed to find an optimal PDT condition, these results suggest that Laserphyrin?-HVJ-E is useful for treatment of prostate cancer with the combination of cytotoxicities of HVJ-E and PDT.

要約(英語): Replication-deficient virus particles, hemagglutinating virus of Japan envelope (HVJ-E), has cytotoxicity to cancer cells, and clinical research on prostate cancer is conducted. To enhance the therapeutic effect of HVJ-E, talaporfin sodium (Laserphyrin?) used for photodynamic therapy (PDT) was encapsulated into HVJ-E to produce a novel photosensitizing drug, Laserphyrin?-HVJ-E, and its therapeutic effect for prostate cancer cells (PC-3) was evaluated. As the results, direct cytotoxicities of HVJ-E and Laserphyrin?-HVJ-E for PC-3 after an administration time of 48 h were almost the same. After PDT with administration of Laserphyrin?-HVJ-E and Laserphyrin? for 10 min, cell survival rates of PC-3 were about 21% and 19%, respectively. Although further study is needed to find an optimal PDT condition, these results suggest that Laserphyrin?-HVJ-E is useful for treatment of prostate cancer with the combination of cytotoxicities of HVJ-E and PDT.

原稿種別: 英語

PDFファイルサイズ: 975 Kバイト